Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

mRNA
The research behind the mRNA-based vaccines used to minimize severe COVID-19 cases has another potential use—fighting cancer.

As the COVID-19 pandemic unraveled in 2020, the world witnessed another stunning occurrence—medical researchers across the globe dropped nearly everything to commit to the development of a vaccine that would protect the population as soon as possible. In less than one year, the time, money and effort that went into fueling such research also fueled a monumental triumph in U.S. medical history—the FDA approval of the first-ever vaccines utilizing mRNA.

Of course, everyone is now abuzz with discussions about mRNA given its important role in combating the novel coronavirus. But while mRNA vaccines are new, they’re certainly not an unfamiliar topic to researchers. They also hold the potential to fight a greater array of diseases and viruses than just COVID-19—including cancer.

You may recall your high school biology teacher explaining how mRNA, or messenger ribonucleic acid, is a molecule that carries genetic instructions from the body’s DNA strands to the cytoplasm, where proteins are made. Because proteins help cellular functions in our body like fighting against illnesses, research began in the 1990s to discover how to harness mRNA’s protein-making power into custom-made protection from diseases or viruses.

When it comes to more traditional routine vaccines, like the flu shot, our body receives a weakened or inactivated form of the targeted virus. This is not the case with mRNA-based vaccines.

In mRNA technology, synthetic mRNA is developed in a lab and, when entering the body, instructs the host to form a predetermined protein in order to trigger an immune response. After producing the appropriate antibodies, the body now wields a blueprint on fighting the virus were it to pop up again—all without the risk of becoming infected or seriously ill to do so.

With COVID-19, the key protein chosen for the vaccine is the “spike” protein, found on the surface of the virus. For other viruses or diseases, it could be a different protein. The magic of synthetic mRNA’s potential is its customization. This flexibility bodes well for other areas of focus, like cancer research.

“The most significant potential of mRNA research is cancer vaccines,” says Sean Marchese, a registered nurse and oncology writer at The Mesothelioma Center who has experience in respiratory and thoracic oncology clinical trials. “The specific targeting mechanisms of mRNA vaccines make them excellent candidates for cancer treatment. We’re seeing this level of effectiveness now with the COVID-19 vaccine.”

The most significant potential of mRNA research is cancer vaccines.

Moderna Inc., the biotech giant responsible for one of two current mRNA vaccines for the COVID-19 virus, doesn’t take the potential of mRNA technology lightly. It’s also applying its research toward immune-oncology, or immunotherapy, to create a cancer vaccine.

“Immunotherapy is taking off in the oncology world, and mRNA vaccines are the next step in that field,” explains Marchese.

Immunotherapy has shown some promise in using the body’s immune system to identify and fight cancerous cells. Just like synthetic mRNA strengthens an immune system’s response to a pathogen, immunotherapy can strengthen an immune system’s response to cancer cells. But it’s not perfect. Studies have found that sometimes immunotherapy drugs are only partially effective for patients, and occasionally they may not work at all.

“Cancer cells vary from patient to patient, so we must develop vaccines that target specific mutations,” says Marchese.

Moderna is aiming to do just that through its research on personalized cancer vaccines. Such a vaccine would utilize next-generation sequencing, a way to analyze genetic variations within diseases, to identify mutations found on a patient’s cancer cells. Moderna’s bioinformatics team would develop algorithms based on this information to encode for each of these mutations in a single mRNA molecule, which is then distributed through a vaccine. This would ideally assist the patient’s body in identifying cancerous cells more easily, thus creating a stronger immune response for treating cancer.

Results from studies have been optimistic. A clinical trial sponsored by Moderna at the University of Arizona expanded in November 2020 to include more participants after showing promising preliminary data on head and neck cancer patients receiving a personalized cancer vaccine in combination with immunotherapy drug Pembrolizumab.

There are setbacks when it comes to mRNA and cancer, however, which is likely why we haven’t seen a mRNA-based cancer vaccine approved just yet.

Immunotherapy is taking off in the oncology world, and mRNA vaccines are the next step in that field

After mRNA instructs your body to form the predetermined protein, it breaks apart and eventually dissipates completely. This works well enough for the COVID-19 virus, but the short-term immune engagement isn’t as effective for cancer cell treatment as mRNA must travel all the way into the body’s lymph nodes to be productive.

A February 2021 study set out to address this shortcoming. Chinese researchers developed and tested an injectable hydrogel—synthetic biomaterials that closely resemble natural living tissue—that contains and stabilizes mRNA, allowing a slower release of mRNA. Administered to mice with melanoma, subjects experienced reductions in tumor size and no further metastasis in the lungs. These findings could be influential in cancer vaccine development if success continues in further trials.

Cancer is complex and using mRNA to develop a cancer vaccine is still in the early stages of research. But the success of mRNA-based vaccines tackling the COVID-19 virus has shone a spotlight on the potential of this versatile approach in cancer care. With a momentous mRNA landmark occurring firsthand in real time, a new era of vaccine technology may be ushered in.

“Researchers have proven the scalability of mRNA vaccine production with COVID-19 vaccines,” says Marchese. “And now we must turn that focus towards cancer prevention and treatment.”


To follow along with Moderna Inc.’s immuno-oncology progress and development of a personalized mRNA-based cancer vaccine, visit modernatx.com/pipeline/therapeutic-areas.

More
articles

CALUMET RIVER pollution
Cancer & Environment

Cleaning Up the Calumet

For decades, industrial and manufacturing waste was dumped into the Grand Calumet River, turning the natural wilderness of the Calumet region into a polluted wasteland. But recent cleanup efforts aim to restore the river and surrounding region to a place of beauty once again.

Read More »
BOOBIE CROWNS
(Y)our Stories

Boobie Queens

Breast cancer warriors can find extra support through Boobie Crowns, an organization with an unconventional way of making you feel like royalty.

Read More »
RUNNING WITH CANCER
Breast Cancer

Running With Cancer

Part-time certified fitness instructor Jennifer Sinkwitts was slated to run the Boston Marathon after an impressive qualifying time—then she was diagnosed with breast cancer. She decided to run anyway.

Read More »
Fashion

Gracefully Bold

Megan Sullivan, founder of With Grace B. Bold, designs elegant, fashion-forward garments that are made to help women feel beautiful and comfortable during a difficult time.

Read More »